Olaparib: A Clinically Applied PARP Inhibitor Protects from Experimental Crohn's Disease and Maintains Barrier Integrity by Improving Bioenergetics through Rescuing Glycolysis in Colonic Epithelial Cells.

Oxid Med Cell Longev · 2021 · PMC8457969 · PMID 34567413

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Unfortunately, TNBS-induced changes in the neutrophil to monocyte ratio (NMR) ( Figure 3(d) ) did not reach statistical significance compared to the vehicle.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.